At the 2014 American Society of Hematology (ASH) Annual Meeting, Dr Andrew Davies (University of Southampton, Southampton, UK) discusses a phase II/III study comparing the efficacy and safety of lenalidomide versus investigators choice in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Studies continue to support the clinical relevance of molecularly distinct subtypes of DLBCL.
This programme has been supported by sponsorship from Celgene
Advertisement